𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study

✍ Scribed by R.-M. Szeimies; P. Radny; M. Sebastian; F. Borrosch; T. Dirschka; G. Krähn-Senftleben; K. Reich; G. Pabst; D. Voss; M. Foguet; R. Gahlmann; H. Lübbert; U. Reinhold

Book ID
108671289
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
264 KB
Volume
163
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a multicenter placebo-control
Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma
✍ E. M. Lemmel; D. Brackertz; M. Franke; W. Gaus; P. W. Hartl; K. Machalke; H. Mie 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 660 KB

In a multicenter placebo-controlled double-blind randomized clinical study, 91 patients with rheumatoid arthritis were given 28 days' treatment with recombinant interferon-gamma (50 micrograms daily for 20 days, then 50 micrograms each second day up to day 28, given by subcutaneous injection). The a

Alefacept in combination with methotrexa
Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study
✍ Philip J. Mease; Dafna D. Gladman; Edward C. Keystone 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA). ## Methods Patients were eligible for this randomized, double‐blind, placebo‐controlled trial if they were ages 18–70 years and had act